Altre lingue Algernon Pharmaceuticals Inc.

Azioni

AGN

CA01559R4008

Mercato chiuso - Canadian Securities Exchange Altri mercati azionari 20:50:41 10/05/2024			Variaz. 5gg	Var. 1 gen.
0,125 ^CAD	+13,64%		+13,64%	+92,31%

30/04	Algernon Pharmaceuticals Inc. riporta i risultati degli utili per il secondo trimestre e i sei mesi conclusi il 29 febbraio 2024	CI
01/04	Algernon Pharmaceuticals intende procedere con il programma di ricerca sull'ictus del farmaco psichedelico Dmt come sua attività principale	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Algernon Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended February 29, 2024	30/04
Algernon NeuroScience and the Centre for Human Drug Research to Present DMT Phase 1 Stroke Clinical Data at the Interdisciplinary Conference on Psychedelic Research June 6 - 8th, 2024	25/04
Algernon NeuroScience and the Centre for Human Drug Research to Present DMT Phase 1 Stroke Clinical Data at the Interdisciplinary Conference on Psychedelic Research June 6 – 8th, 2024	24/04
Algernon Pharmaceuticals CEO Christopher J. Moreau to Be Featured on Radius Research's Pitch, Deep Dive and Q&A Webinar on April 16th, 2024	11/04
Algernon Pharmaceuticals Inc. announced that it has received CAD 0.017 million in funding	10/04
Algernon Pharmaceuticals Inc. announced that it expects to receive CAD 0.017 million in funding	03/04
Algernon Pharmaceuticals to Move Forward with Psychedelic Drug DMT Stroke Research Program as its Lead Asset	01/04
Algernon Pharmaceuticals to Move Forward with Psychedelic Drug Dmt Stroke Research Program as Its Lead Asset	01/04
Algernon Pharmaceuticals Strikes Deal to Advance Ifenprodil in Chronic Cough Treatment	28/03
Algernon Pharmaceuticals Says Acquisition of Ifenprodil Program Completed by US Company	27/03
Canadian Investment Regulatory Organization Trade Resumption - AGN	27/03
Algernon Pharmaceuticals Announces Closing of the Acquisition of its Chronic Cough Research Program by U.S. Based Seyltx for USD $2M and a 20% Equity Position	27/03
Canadian Investment Regulatory Organization Trading Halt - AGN	27/03
Algernon Pharmaceuticals Inc. acquired 20% stake in Seyltx, Inc.	27/03
Algernon Pharmaceuticals Receives Notice of Intention to Grant from Chinese Patent Office for Repirinast to Treat CKD	31/01
Algernon Pharmaceuticals Receives Notice of Intention to Grant from Chinese Patent Office for Repirinast to Treat CKD	31/01
Algernon Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended November 30, 2023	25/01
Algernon Pharmaceuticals Inc. Announces Notice of Allowance for Ifenprodil Patent in Japan for Idiopathic Pulmonary Fibrosis	24/01
Algernon Pharmaceuticals Announces Notice of Allowance for Ifenprodil Patent in Japan for Idiopathic Pulmonary Fibrosis	11/01
Algernon Pharmaceuticals Announces Notice of Allowance for Ifenprodil Patent in Japan for Idiopathic Pulmonary Fibrosis	11/01

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Algernon Pharmaceuticals Inc.

Azioni

AGN

CA01559R4008

Altre lingue

Filtri